Press Release Distribution
Pricing
Customer Support
(800) 998-2927
Login
Log In
All Categories
Business
Entertainment
Health
Finance
Other
Tagged
jak-inhibitors
Press Release
Aug 23, 2018
Pfizer's Xeljanz Begins to Shift the Treatment Paradigm in Ulcerative Colitis (UC) With Early Launch Metrics Largely Favorable for the Brand
The majority of patients started on Xeljanz have failed multiple biologics, but some gastroenterologists see the brand securing a role in the pre-biologic space in the near future, according to the latest quarterly report from Spherix Global Insights
Read More
First
Prev
1
Next
Last